Multi-Cancer Early Detection for Health Systems: Four Adoption Models
The American Cancer Society estimates that over 1,600 Americans die from cancer each day.1
No longer just a technology with promise, the Galleri multi-cancer early detection (MCED) test has arrived. Learn how leading health systems are implementing cutting-edge programs to screen for cancer and intervene early.
- Ochsner is using MCED tests to address social determinants of health
- HCA Healthcare and Sarah Cannon are developing processes for comprehensive cancer care from screening to diagnosis, focusing on clinical decision support, referrals, and nurse navigation earlier in a patient’s cancer detection journey
- Providence, a leader in genomics, is conducting enhanced screening for patients who tested positive for hereditary risk
- Veterans Health Administration using MCED tests to improve population health
Cancer won’t wait. Learn how to screen for cancer early.
The Galleri test does not detect all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri should be used in addition to healthcare provider recommended screening tests. For Important Safety Information, visit https://www.galleri.com/safety-information.
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “No Cancer Signal Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.